"Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians," researchers write in Seminars in Cutaneous Medicine and Surgery.
Dermatologists play a significant role in screening for psoriasis comorbidities and asking about shortness of breath as a routine part of medical history-taking, shows a study published in BMJ.
A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
Physicians should be aware of the warning signs that a biologic agent could be to blame when patients experience subacute or rapidly progressive neurologic changes, researchers say.
Acute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.
A small study shows that ultrasound may be a viable diagnostic tool to determine whether patients have psoriasis or psoriatic arthritis, Italian researchers report.
A JAMA Dermatology study raises the possibility of adopting the NASH FibroSure test to detect hepatic fibrosis in psoriasis patients and minimize the number of liver biopsies.
Fear associated with perceived pain from injectable biologics has been shown to be successfully addressed by employing anchoring bias interventions, researchers report in JAMA Dermatology.
The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
NEJM analysis proves what has been suspected for decades: Alcohol can be more deadly in the psoriasis population as compared to non-psoriasis patients.
Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications.
Survey highlights the challenges of controlling psoriasis flares.
Experts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.
The American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Switching from originator to biosimilar shows no significant impact on drug survival in plaque psoriasis, but outcomes differ, researchers report.
A pediatric dermatologist addresses important differences in children with psoriasis, versus adults.
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (©FreeBirdPhotos/Shutterstock.com)
New research offers strong evidence that vascular inflammation and risk of having a major adverse cardiovascular event increases with psoriasis duration.
Of several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.
Metabolomics could provide new statistical methods to help monitor psoriasis disease and progression.
A global community of physicians cooperated to share experiences with systemic drugs for pediatric psoriasis, and to get experience with a joint registry. A uniform dataset could be tapped to learn more about disease manifestations and treatment outcomes
Psoriatic arthritis can often go undiagnosed in patients with psoriasis, and an earlier diagnosis is critical to prevent the adverse effects of psoriatic arthritis, according to an expert.
The approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
